Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Single Arm Investigator-initiated Study to Investigate the Safety of Combining the Antibody Magrolimab With Standard First Line Platinum-based Chemotherapy (With Cisplatin / Gemcitabine) in Advanced Urothelial Carcinoma

Next Previous
Trial Profile

A Phase 1, Single Arm Investigator-initiated Study to Investigate the Safety of Combining the Antibody Magrolimab With Standard First Line Platinum-based Chemotherapy (With Cisplatin / Gemcitabine) in Advanced Urothelial Carcinoma

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Magrolimab (Primary)
  • Indications Bladder cancer; Carcinoma; Urogenital cancer
  • Focus Adverse reactions
  • Acronyms MACOCUC-01

Most Recent Events

  • 05 Jul 2024 Status changed from recruiting to withdrawn prior to enrolment.
  • 03 Jul 2023 Status changed from not yet recruiting to recruiting.
  • 08 Jun 2023 Planned initiation date changed from 1 Apr 2023 to 1 Jul 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top